IDEA2 Global Assumptions, hypotheses and key questions

Name:	John Priatel
Team:	ME Therapeutics
What are the key assumptions you have identified? (List at least 3)	 Do anti-G-CSF antibodies improve antitumour responses (Will they show efficacy in combination with checkpoint inhibitors)? Will our humanized anti-human G-CSF antibody work similarly as the surrogate mouse anti-GSF antibody in rodent tumour models? Will our anti- G-CSF antibody be safe (nontoxic)?
List experts, users, anti-users, customers, buyers, tech-people, recipients of technology, marketing	 Clinical oncologists Cancer immunotherapy scientists Venture capital investors